Kristen K Ellard1, Emily E Bernstein2, Casey Hearing3, Ji Hyun Baek4, Louisa G Sylvia5, Andrew A Nierenberg5, David H Barlow6, Thilo Deckersbach5. 1. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. Electronic address: kellard@mgh.harvard.edu. 2. Department of Psychology, Harvard University, Cambridge, MA, USA. 3. Department of Psychology, George Washington University, USA. 4. Department of Psychiatry, Sungkyunkwan University Samsung Medical Centre, Gyeonggi-do, Republic of Korea. 5. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Psychology, Boston University, Boston, MA, USA.
Abstract
BACKGROUND:Comorbid anxiety in bipolar disorder (BD) is associated with greater illness severity, reduced treatment response, and greater impairment. Treating anxiety in the context of BD is crucial for improving illness course and outcomes. The current study examined the feasibility, acceptability and preliminary efficacy of the Unified Protocol (UP), a transdiagnostic cognitive behavioral therapy, as an adjunctive treatment to pharmacotherapy for BD and comorbid anxiety disorders. METHODS:Twenty-nine patients with BD and at least one comorbid anxiety disorder were randomized to pharmacotherapy treatment-as-usual (TAU) or TAU with 18 sessions of the UP (UP+TAU). All patients completed assessments every four weeks to track symptoms, functioning, emotion regulation and temperament. Linear mixed-model regressions were conducted to track symptom changes over time and to examine the relationship between emotion-related variables and treatment response. RESULTS:Satisfaction ratings were equivalent for both treatment groups. Patients in the UP+TAU group evidenced significantly greater reductions over time in anxiety and depression symptoms (Cohen's d's>0.80). Baseline levels of neuroticism, perceived affective control, and emotion regulation ability predicted magnitude of symptom change for the UP+TAU group only. Greater change in perceived control of emotions and emotion regulation skills predicted greater change in anxiety related symptoms. LIMITATIONS: This was a pilot feasibility and acceptability trial; results should be interpreted with caution. CONCLUSIONS: Treatment with the UP+TAU was rated high in patient satisfaction, and resulted in significantly greater improvement on indices of anxiety and depression relative to TAU. This suggests that the UP may be a feasible treatment approach for BD with comorbid anxiety.
RCT Entities:
BACKGROUND: Comorbid anxiety in bipolar disorder (BD) is associated with greater illness severity, reduced treatment response, and greater impairment. Treating anxiety in the context of BD is crucial for improving illness course and outcomes. The current study examined the feasibility, acceptability and preliminary efficacy of the Unified Protocol (UP), a transdiagnostic cognitive behavioral therapy, as an adjunctive treatment to pharmacotherapy for BD and comorbid anxiety disorders. METHODS: Twenty-nine patients with BD and at least one comorbid anxiety disorder were randomized to pharmacotherapy treatment-as-usual (TAU) or TAU with 18 sessions of the UP (UP+TAU). All patients completed assessments every four weeks to track symptoms, functioning, emotion regulation and temperament. Linear mixed-model regressions were conducted to track symptom changes over time and to examine the relationship between emotion-related variables and treatment response. RESULTS: Satisfaction ratings were equivalent for both treatment groups. Patients in the UP+TAU group evidenced significantly greater reductions over time in anxiety and depression symptoms (Cohen's d's>0.80). Baseline levels of neuroticism, perceived affective control, and emotion regulation ability predicted magnitude of symptom change for the UP+TAU group only. Greater change in perceived control of emotions and emotion regulation skills predicted greater change in anxiety related symptoms. LIMITATIONS: This was a pilot feasibility and acceptability trial; results should be interpreted with caution. CONCLUSIONS: Treatment with the UP+TAU was rated high in patient satisfaction, and resulted in significantly greater improvement on indices of anxiety and depression relative to TAU. This suggests that the UP may be a feasible treatment approach for BD with comorbid anxiety.
Authors: Stephanie Salcedo; Alexandra K Gold; Sana Sheikh; Peter H Marcus; Andrew A Nierenberg; Thilo Deckersbach; Louisa G Sylvia Journal: J Affect Disord Date: 2016-05-14 Impact factor: 4.839
Authors: J Christopher Fowler; Ruby Charak; Jon D Elhai; Jon G Allen; B Christopher Frueh; John M Oldham Journal: J Psychiatr Res Date: 2014-08-10 Impact factor: 4.791
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Dominic H Lam; Edward R Watkins; Peter Hayward; Jenifer Bright; Kim Wright; Natalie Kerr; Gina Parr-Davis; Pak Sham Journal: Arch Gen Psychiatry Date: 2003-02
Authors: Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta Journal: Am J Psychiatry Date: 2013-11 Impact factor: 18.112
Authors: Steven H Jones; Gina Smith; Lee D Mulligan; Fiona Lobban; Heather Law; Graham Dunn; Mary Welford; James Kelly; John Mulligan; Anthony P Morrison Journal: Br J Psychiatry Date: 2014-09-11 Impact factor: 9.319
Authors: Paolo Fusar-Poli; Marco Solmi; Natascia Brondino; Cathy Davies; Chungil Chae; Pierluigi Politi; Stefan Borgwardt; Stephen M Lawrie; Josef Parnas; Philip McGuire Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Kristen K Ellard; Aishwarya G Gosai; Emily E Bernstein; Navneet Kaur; Lousia G Sylvia; Joan A Camprodon; Darin D Dougherty; Andrew A Nierenberg; Thilo Deckersbach Journal: J Affect Disord Date: 2018-06-02 Impact factor: 4.839
Authors: Bonifacio Sandín; Julia García-Escalera; Rosa M Valiente; Victoria Espinosa; Paloma Chorot Journal: Int J Environ Res Public Health Date: 2020-11-10 Impact factor: 3.390